Mercury Labs Stock Price Today (NSE: MERCURYLAB)
Fundamental Score
Mercury Labs Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Mercury Labs share price today is ₹860.00, up +0.00% on NSE/BSE as of 23 June 2026. Mercury Labs (MERCURYLAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹102.07 (Cr). The 52-week high for MERCURYLAB share price is ₹976.00 and the 52-week low is ₹805.00. At a P/E ratio of 20.79x, MERCURYLAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 5.94% and a debt-to-equity ratio of 0.11.
Mercury Labs Share Price Chart — NSE/BSE Historical Performance
Mercury Labs share price chart: -2.76% return over the past month. 52-week high ₹976.00, 52-week low ₹805.00.
Mercury Labs — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹840.00 | ₹860.00 | ₹840.00 | ₹860.00 | 15.00 (Cr) | |
| ₹877.00 | ₹877.00 | ₹831.00 | ₹832.05 | 66.00 (Cr) | |
| ₹826.00 | ₹877.00 | ₹826.00 | ₹848.95 | 90.00 (Cr) | |
| ₹861.00 | ₹861.00 | ₹835.80 | ₹835.95 | 63.00 (Cr) | |
| ₹832.35 | ₹898.00 | ₹832.35 | ₹874.95 | 6.00 (Cr) | |
| ₹976.00 | ₹976.00 | ₹831.00 | ₹876.35 | 210.00 (Cr) | |
| ₹853.00 | ₹853.00 | ₹853.00 | ₹853.00 | 25.00 (Cr) | |
| ₹900.00 | ₹900.00 | ₹864.55 | ₹869.90 | 283.00 (Cr) | |
| ₹890.55 | ₹897.00 | ₹868.00 | ₹893.55 | 57.00 (Cr) | |
| ₹868.55 | ₹868.55 | ₹868.55 | ₹868.55 | 3.00 (Cr) |
Mercury Labs — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹868.55 | ₹976.00 | ₹826.00 | ₹860.00 | -0.98% | |
| ₹843.45 | ₹925.00 | ₹826.00 | ₹868.55 | +2.98% | |
| ₹825.00 | ₹950.00 | ₹805.00 | ₹843.45 | +2.24% |
AI Research Briefing
Powered by Gemini · 2026-04-08
Micro-cap pharma facing strong headwinds; avoid until clear turnaround signs emerge.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major positive catalysts found after live search. Mercury Labs closed trading on April 1st for FY26 results. The stock declined 1.23% in the week ending April 2nd, closing at underperforming the Sensex. MarketsMojo downgraded the stock to 'Strong Sell' on March 27th due to bearish technicals and weak fundamentals.
CORE STORY (THE REAL GAME)
- Stock downgraded to Strong Sell
- Trading below key moving averages
- Micro-cap liquidity risk
- Positive FY26 results
- Significant order wins
- Improvement in technical indicators
- Micro/SME cap: liquidity risk
- Downgraded to Strong Sell
- Delayed plant commissioning
No institutional interest (FII/DII: 0.0%)
Indian pharma sector aiming for global innovation hub status, but Mercury Labs struggles to capitalize.
Profit converting to cash (Free Cash Flow 5Y: ₹5.2 Cr)
Next 3-6 months dependent on FY26 results. Unlikely to see significant upside without a clear growth catalyst.
Primary Thesis Risk
Continued underperformance and lack of growth catalysts will lead to further downside.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Mercury Labs Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Mercury Labs Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MERCURYLAB across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 20.79 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (228.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.11)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (13.17x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (73.66%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Below-Average Return on Equity (5.94%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.94%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Weak Earnings Growth (-0.82% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-0.82% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Mercury Labs vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Mercury Labs with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Mercury LabsMercury Labs...Selected✓ MERCURYLAB • 538964 | 38.6/100 | ₹860.00₹860 | ₹102.07₹102.07 | 20.79Average 20.8 Average | 5.94%Poor 5.94% Poor | 8.94%Poor 8.94% Poor | 0.11Excellent 0.1 Excellent | -0.82%Poor -0.82% Poor | 5.57%Good 5.57% Good | 0.41% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Mercury Labs PE Ratio History
Historical price-to-earnings ratio for MERCURYLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹47.12 | ₹896.00 | 19x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Mercury Labs Dividend History
Annual cash dividends paid by MERCURYLAB — dividend yield 0.41%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹0.42 Cr |
| FY 2024 | ₹0.42 Cr |
| FY 2023 | ₹0.42 Cr |
| FY 2022 | ₹0.24 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Mercury Labs Quarterly Performance
Latest quarterly metrics for MERCURYLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
4.51%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
228.00%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
5.57%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-0.82%
Compounded annual net profit growth over 5 years
Mercury Labs Technical Indicators
SMA 50, SMA 200, RSI and volume signals for MERCURYLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Mercury Labs Financial Statements
Annual income statement, balance sheet and cash flow for Mercury Labs (MERCURYLAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Mercury Labs
About MERCURYLAB (Mercury Labs)
Mercury Labs (MERCURYLAB) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current... market capitalisation of ₹102.07 (Cr). Mercury Labs has delivered a Return on Equity (ROE) of 5.94% and a ROCE of 8.94%. The debt-to-equity ratio stands at 0.11, reflecting the company's capital structure. Investors tracking MERCURYLAB share price can monitor key metrics including P/E ratio, promoter holding of 73.66%, and quarterly earnings growth.
Company Details
MERCURYLAB Share Price: Frequently Asked Questions
What is the current share price of Mercury Labs?
Mercury Labs (MERCURYLAB) trades at ₹860.00 on NSE and BSE. Market cap ₹102.07 (Cr). Educational data only.
What is the P/E ratio of Mercury Labs?
Mercury Labs has a P/E of 20.79x vs industry average 31.77x.
What is the Bull Run score for Mercury Labs?
Mercury Labs has a Bull Run score of 38.6/100 based on 25+ financial parameters.
Does Mercury Labs pay dividends?
Mercury Labs has a dividend yield of 0.41%. Past dividends don't guarantee future payments.
What is the ROE of Mercury Labs?
Mercury Labs has ROE of 5.94%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Mercury Labs?
Mercury Labs has debt-to-equity of 0.11.
Is Mercury Labs a good investment?
Bull Run gives Mercury Labs a score of 38.6/100. This is not investment advice — consult a SEBI-registered advisor.